Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126708921 | 12670892 | 1 | I | 20160814 | 0 | 20160819 | 20160819 | DIR | 66.00 | YR | M | N | 163.00000 | LBS | 20160818 | Y | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126708921 | 12670892 | 1 | PS | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | FS6X921 | 20171231 | 0 | 8 | DF | PRN | ||||||
| 126708921 | 12670892 | 3 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
| 126708921 | 12670892 | 4 | C | FINASTERIDE. | FINASTERIDE | 1 | 0 | ||||||||||||
| 126708921 | 12670892 | 6 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126708921 | 12670892 | 1 | Type 1 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126708921 | 12670892 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126708921 | 12670892 | Blood glucose increased | |
| 126708921 | 12670892 | Product quality issue | |
| 126708921 | 12670892 | Therapy non-responder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126708921 | 12670892 | 1 | 20160813 | 20160815 | 0 |